Latest news
{{'2026-11-16T15:00:00Z' | dateFormatFilter}}
Wegovy® resulted in a BMI reduction of 10% or more in almost 80% of children with obesity aged 6 to under 12, compared to 0% with placebo in STEP Young trial, published in The New England Journal of Medicine
{{'2026-11-15T13:00:00Z' | dateFormatFilter}}
Novo's CagriSema was associated with 25% mean weight loss among early responders in a post hoc analysis of REDEFINE 1 presented at ObesityWeek® 2026
{{'2026-11-14T17:15:00Z' | dateFormatFilter}}
Novo’s Wegovy® was associated with a reduction in food noise according to real-world studies at ObesityWeek® 2026
Investors
Share price
{{priceData.date}} {{priceData.time}}
{{priceData.currentPrice}}
{{priceData.currency}}
Go to stock watch
{{priceData.change}} {{priceData.currency}}